French group Ipsen to have branch in Brazil
Valor Econômico
French group Ipsen should announce on Wednesday its entrance in the Brazilian market. Specialized in biotechnology, the multinational sells botulinic toxin aimed, mainly, at therapeutic purposes. Ipsen already operates in Brazil through partnerships with companies that operate in this segment. The French group now intends to put up a branch office in Brazil so as to have direct contact with its clients. The Brazilian market is considered a strategic market for the company and it has strong growth potential.
With earnings of nearly € 1.03 billion in 2008, the group is present in 40 countries. The company operates in the international market with more than 20 products. The research strategy of the company is based on the combination of special products in the areas of therapeutic oncology, endocrinology and neurology. The company, whose shares are listed in the Paris Euronext, has four research centers, located in Paris, Boston, Barcelona and London. The company also sells drugs to fight Parkinson's disease and endocrine dysfunction.
The botulinic toxin market Ipsen wants to heavily enter in the country is considered promising. Besides selling the product for therapeutic purposes, Ipsen also works in the aesthetic area with Dysport as its flagship. In Brazil, the Dysport brand is distributed by the Galderma company, whose main rival is Botox from the Allergan company.
The botulinic toxin is used in large scale by medical specialties such as ophthalmology and neurology for the treatment of diseases such as strabismus, spasticity, torticollis and blepharospasms. It has been more than 10 years since the product started being applied by dermatologists and aesthetic plastic surgeons in procedures to ease wrinkles in the face, a clearly booming market.